Healthcare provider and patient perspectives on the implementation of pharmacogenetic-guided treatment in routine clinical practice

被引:0
|
作者
Kaur, Gurveer [1 ]
Nwabufo, Chukwunonso K. [1 ,2 ,3 ]
机构
[1] OneDrug Inc, Toronto, ON, Canada
[2] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON, Canada
[3] Hosp Sick Children, Program Translat Med, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
adverse drug reactions; healthcare provider; implementation; patient; personalized medicine; pharmacogenetics; pharmacogenetic testing device; point-of-care; PHARMACISTS PERCEPTION; CONTEXT; EXPERIENCES; SUPPORT; POINT;
D O I
10.1097/FPC.0000000000000541
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
ObjectiveThis study aims to understand patient and healthcare provider perspectives on the integration and application of pharmacogenetics (PGx) testing in routine clinical practice.MethodsTwo anonymous online surveys were distributed globally for healthcare providers and patients respectively on the Qualtrics platform (version 3.24). The surveys were distributed through social platforms, email, and posters with QR codes from 27 October 2023 to 7 March 2024. The surveys evaluated participant familiarity with PGx, previous experience with PGx testing, perceived implementation challenges, and opinions on point-of-care (PoC) PGx testing devices.ResultsThis study collected 78 responses from healthcare providers and 98 responses from patients. The results revealed that 64% of healthcare providers had some level of familiarity with PGx, however, PGx testing in clinical practice was low. The primary challenges identified by healthcare providers included limited access to testing and lack of knowledge on PGx test interpretation. In contrast, 52% of patient respondents were aware of PGx testing, with a significant association between awareness and positive opinions toward PGx. Both healthcare providers and patients recognized the value of PoC PGx testing devices, with 98% of healthcare providers and 71% of patients believing PoC devices would improve the accessibility and implementation of PGx testing. Comparative analysis revealed a statistically significant difference in PGx awareness between healthcare providers and patients, with providers being more informed.ConclusionImproved PGx awareness, training, clinical guidelines, and PoC PGx testing devices may help promote the implementation of PGx-guided treatments in routine clinical practice.
引用
收藏
页码:236 / 245
页数:10
相关论文
共 50 条
  • [1] Pharmacogenetic-Guided Treatment of Depression: Real-World Clinical Applications, Challenges, and Perspectives
    Zanardi, Raffaella
    Manfredi, Elena
    Montrasio, Cristina
    Colombo, Cristina
    Serretti, Alessandro
    Fabbri, Chiara
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (03) : 573 - 581
  • [2] Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin
    Verhoef, Talitha I.
    Schalekamp, Tom
    Redekop, William K.
    de Boer, Anthonius
    Maitland-van der Zee, Anke-Hilse
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2010, 10 (04) : 375 - 378
  • [3] Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility
    Bradley, Paul
    Shiekh, Michael
    Mehra, Vishaal
    Vrbicky, Keith
    Layle, Stacey
    Olson, Marilyn C.
    Maciel, Alejandra
    Cullors, Ali
    Garces, Jorge A.
    Lukowiak, Andrew A.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2018, 96 : 100 - 107
  • [4] Patient and Healthcare Provider Perspectives on the Implementation of a Web-Based Clinical Communication System for Cancer: A Qualitative Study
    Petrovic, Bojana
    O'Brien, Mary Ann
    Liddy, Clare
    Afkham, Amir
    McGee, Sharon F.
    Morgan, Scott C.
    Segal, Roanne
    Bender, Jacqueline L.
    Sussman, Jonathan
    Urquhart, Robin
    Fitch, Margaret
    Schneider, Nancy D.
    Grunfeld, Eva
    CURRENT ONCOLOGY, 2022, 29 (11) : 8401 - 8414
  • [5] A systematic review of cost effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives
    Verhoef, Talitha I.
    Redekop, William K.
    Darba, Josep
    Geitona, Mary
    Hughes, Dyfrig A.
    Siebert, Uwe
    de Boer, Anthonius
    Zee, Anke-Hilse Maitland-van der
    PHARMACOGENOMICS, 2010, 11 (07) : 989 - 1002
  • [6] Application of pharmacogenetic/pharmacogenomic data to personalize treatment in routine clinical practice. A narrative review
    Sanchez Pozo, Antonio
    Montero Gomez, Almudena
    FARMACIA HOSPITALARIA, 2024, 48 : S5 - S12
  • [7] Application of pharmacogenetic/pharmacogenomic data to personalise treatment in routine clinical practice. A narrative review
    Sanchez Pozo, Antonio
    Montero Gomez, Almudena
    FARMACIA HOSPITALARIA, 2024, 48 : TS5 - TS12
  • [8] Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups
    Dietz, Nicholas
    Ruff, Christian
    Giugliano, Robert P.
    Mercuri, Michele F.
    Antman, Elliott M.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 317 : 159 - 166
  • [9] The COAG and EU-PACT Trials: What is the Clinical Benefit of Pharmacogenetic-Guided Coumarin Dosing During Therapy Initiation?
    Baranova, E. V.
    Asselbergs, F. W.
    de Boer, A.
    Maitland-van der Zee, A. H.
    CURRENT MOLECULAR MEDICINE, 2014, 14 (07) : 841 - 848
  • [10] Patient and provider perspectives on implementation barriers and facilitators of an integrated opioid treatment and HIV care intervention
    Alexis Cooke
    Haneefa Saleem
    Saria Hassan
    Dorothy Mushi
    Jessie Mbwambo
    Barrot Lambdin
    Addiction Science & Clinical Practice, 14